OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Share-volume news based on ?very little new facts - I guess it's the 20p-barrier acting as a mrker; but with only 3-4p as cash, the rest, 18p is largely hope at least until Approval update late 2008.

I'd be happier with lower ( than 20p), before taking nearly a year-long punt in these markets.

seemed to have turned the tide, closing positions and buying at extra value i should think and of course the New Yr tips - it normally features somewhere, anyone read anything?

Oxford BioMedica "buy"

Monday, 10th December 2007
Panmure Gordon & Co

LONDON, December 10 (newratings.com) - Analysts at Panmure Gordon reiterate their "buy" rating on Oxford BioMedica Plc (ticker: OXB-GBX). The target price is set to 69p.

In a research note published this morning, the analysts mention that the Data Safety Monitoring Board (DSMB) has recommended the continuation of the Phase III TRIST trial of TroVax in renal cancer, after the second interim analysis has been completed. The fact that the DSMB has recommended the trail to continue without any changes to the protocol is encouraging, the analysts say.

I don't think this "Rec" has much worth - being nearly a month old.

OXB will rise or fall on the Results, in the second half of 2008, unless there is a "stop" earlier - that's why the sp is falling week by week.
+Look at Panamure Gordon's own sp, to see how good the Market judges their performance . . . . Oh dear.

You are absolutely right, hangon. How can Panmure Gordon gives any recommendation when their graph looks like this...

Panmure Gordon are not worth a shit look at there recommendation for wng..Worthington Nicholls i hold (oxb) long .forget what Panmure Gordon say .

Recent RNS - can someone explain what it means - ?

FWIW it looks like Prudential ( subsidary?) has sold close-on 900,000 shares -


Today, the sp fell 3% possibly on this news, but typical of a "No-News" - during

I'd say it's done well to only fall that much today based on the carnage taking place in the markets today.

Agree even ASM is down 4%+ with out any news.

More good news.

Oxford Biomedica's MolMed's TK therapy gets regulatory nod for Phase III start
AFX


LONDON (Thomson Financial) - Oxford Biomedica PLC said its partner MolMed has received regulatory approval to start a Phase III trial of TK therapy for high risk acute leukaemia.

The start of a Phase III trial of TK therapy triggers an undisclosed milestone payment to Oxford BioMedica, the company said in a statement.

'This approval is particularly meaningful also because TK is one of the very few cell/gene therapies in Phase III all over the world, and thus could be among the very first ones to obtain marketing approval,' Marco Dieci, director of quality & regulatory compliance at MolMed said.

tfn.newsdesk@thomson.com

sim/tsm/jlc
http://moneyam.uk-wire.com/cgi-bin/articles/200801220700362290M.html

It's good to read OXB is starting new trials, but we must not get too excited, these can go on for years and there is always "risk" they might not deliver...... So, it's good news - but not what we need this year.

Drifting down again,when will it reach the bottom?

I was very happy to buy a few at 8.5 pence a few years ago (now sold) - that level is unlikely again, unless there is some hitch with Trials - always a risk, although we might like to ignore it. I'm not buying right now as every penny is important at such prices and I don't think the Market generally is anywhere near the bottom.

US investigators qre looking into the deals perpetuated by sub-prime mortgage brokers (in the US), this may be good news - although horse-bolting and stable door springs to mind. We cannot know where this will lead and I suspect the Draught will be felt here and could depress our Markets, even those in Bio/Pharma - that is why OXB is falling right now.IMHO.

Is there any "reason" for OXB's fall, other than general woes - still, there is no point in buying today if it's cheaper tomorrow. Other Pharmas have fallen also so it's not aimed at this one only....unless you know what?

Oh dear!
A writer this weekend needs to fill their column and we see 4p added to the sp based on - er, rumour regurgitated - that Sanofi is about to pay good money to buy OXB - well, if that was their intention, they'd have struck The Deal way back and savved themselves a wad of cash - although ( as Now) they'd have to wait a couple of years to know if their hunch paid off!
-and whoever paid out the money might (?) never work again Doh!

This rise is no more than "maybe" - unless OXB has issued an RNS - but I doubt AK would sell now, anyway - for IF the Trials come good (end 2008?), then the value will be higher ( provided they secure a US partner) and Sanofi is quite happy having the Euro-zone . . . . . with considerably less money at risk.

Until these Trials are concluded and documents signed - OXB is "probably priced right" and beyond 2008, I hope we shall see long-term strength, but in these Markets it is likley to fall back since this latest rise is no more that Weekend Writing - IMHO.
If this is the case then, expect the sp to drift back - don't pay too much!

What no-one seems to understand is "why" Big Pharma doesn't buy all these small-fry ( inc OXB and several others)......simple....it's because they have layers of Managers working their life on a specific product and they all guard their positions - just where does a new "maybe product" fit-in? Are you going to give it to a Junior, so they sinik or swim depending on the Trial outcome? Grief, nuce if it 's Good - but who would risk their career should it turn Bad (and 90% drugs fail).
OR
Do you give it to a big-player on the top floor - and will they put any effort into the product - or will they see this as a side-line that is draining resources from their income?
These are the reasons a Big Pharma doesn't want to take the risky part of development - indeedd most of their "Research Spend" is trying to avoid losing to Generic Makers, always a threat to slaries today....let alone ten years down the line ( OXB has been this long!).

Hangon having said all that maybe just sometimes where there is smoke there is fire. OXB has drifted down because of the protracted trial period it is likely Sanofi know how well or otherwise these trials are proceeding.

Thanks Halifax, but NO!
Patient-Trials are 'blind' . . . . . sometimes "double blind"
- otherwise it is too easy to adjust them, leading to the risk of fraud - Only when the trial is finished will any sense be made of the results . . . but I don't think Sanofi is only interested in this Trial - rather it's a long-term partnership adding value to their existing research.

The only smoke was in the Writer's eyes ( the weekend article), and I suggest this is nothing but old-rumour - and very nice for MM's - for any churning of stocks is profitable - - - - - - but any Bid is the wrong-side of the Trial results (late 2008? - maybe into 2009), as explained - and 50p is way too high "now".

No Pharma can do "due dillegence" when factor-80% of the value of the business hangs in the balance. If the Trial fails- the sp will bomb, maybe 5p, - there is about 2p as cash.....and an awful lot of shares in issue!

Now, a 50p Bid? . . . it makes no sense, IMHO.
(Buys are only maginally higher than Sells, mid-day today)

Huge trade @ 22.5p over 19m shares or 4.3m deal.

Any ideas??

Does this transaction mean OXB is now in play? Who kew it was going to happen?

Now looking interesting

STOCKWATCH Oxford Biomedica up on bid speculation; Evo reiterates 'buy'

LONDON (Thomson Financial) - Shares in Oxford Biomedica PLC jumped in
midmorning deals following reports in the Mail on Sunday speculating on hopes of
a bid for the company by French pharmaceutical giant Sanofi-Aventis, with
Evolution securities reiterating its 'buy' stance.
At 11.05 am, Shares in Oxford Biomedica were up 4 at 22-3/4, while the FTSE
small cap index was down 3.4 at 3136.7.
The Mail on Sunday reported that City sources believe a deal to be imminent,
with Oxford Biomedica Chief executive Alan Kingsman said to be holding out for
an offer above 50 pence a share.
The report noted Sanofi's licensing deal signed last year with Oxford for
its TroVax drug, saying it could cost up to 386 mln stg if the drug is as
successful as some analysts are to be believed.
The Mail on Sunday continued saying that even at 50 pence per share, buying
Oxford Biomedica would cost Sanofi less than its potential costs under the
TroVax licensing deal.
In a note to clients published this morning, Evolution Securities said
Oxford Biomedica has been a conspicuous casualty of the 'flight from risk' seen
in financial markets over the past six months.
The broker added the company has a solid licensing deal with a quality
partner in Sanofi for its lead product TroVax which looks to underpin a target
price well above the current market price of the stock.
In conclusion, Evolution Securities said, in its view the share price fall
over the past 5-6 months has been excessive and leaves the company vulnerable to
speculative action, therefore reiterating its 'buy' stance and target price of
70 pence.